Search results
Results from the WOW.Com Content Network
Bamlanivimab and etesevimab, administered together, are authorized in the United States for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 ...
The CDC estimates that, between February 2020 and September 2021, only 1 in 1.3 COVID-19 deaths were attributed to COVID-19. [2] The true COVID-19 death toll in the United States would therefore be higher than official reports, as modeled by a paper published in The Lancet Regional Health – Americas. [3]
During times of economic distress such as the COVID-19 pandemic or the 2008 recession, harmful rates of drug use has been seen to increase in populations experiencing joblessness and disadvantaged populations; [152] [201] moreover, Carpenter et al. found evidence that economic downturns lead to increases in the intensity of prescription pain ...
Supporting and improving mental health could have a direct impact on substance use among teens in the United States, according to a new study from the US Centers for Disease Control and Prevention.
It's important to understand why teens use or misuse drugs, so the right resources and education can help them, Dr. Nora Volkow, director of the National Institute on Drug Abuse, wrote in an email.
The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19. [ 211 ] [ 217 ] According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021 ...
Previous research shows that prescription amphetamine use in adults has been increasing in the United States, increasing 70% from 2011 to 2021, with a larger spike during the COVID-19 pandemic.
In November 2023, the FDA revised the EUA for nirmatrelvir/ritonavir to authorize EUA- or NDA-labeled nirmatrelvir/ritonavir for the treatment of mild-to-moderate COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb), who are at high risk for progression to severe COVID‑19, including hospitalization. [18]